Reports
Sale
Onychomycosis Market Size, Share, Analysis, Report, Forecast: By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy, Others: By Type: Distal Subungual Onychomycosis, White Superficial Onychomycosis, Other Types; By Route of Administration; By End User; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Onychomycosis Market Outlook
The onychomycosis market size was valued at USD 4 billion in 2023 in the 7 major markets, driven by the rising prevalence of onychomycosis especially in the geriatric population across the major markets. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 to achieve a value of USD 6.3 billion by 2032.
Onychomycosis: Introduction
Nail fungus is a common nail infection that initiates as a white or yellow-brown spot under the tip of the fingernail or toenail. The nail starts discoloring, thickening, and crumbling at the edge as the infection goes deep. Nail fungus is also called onychomycosis. When fungus infects the areas between the toes and the skin of the feet, it's called athlete's foot (tinea pedis).
Developments such as oral antifungal drugs like itraconazole (Sporanox), stimulate new nail growth free of infection, slowly replacing the infected part. Another innovation is medicated nail polish ciclopirox (Penlac) prescribed by healthcare professionals to be used once a day for as long as 6 weeks or more. Additionally, medicated nail cream, more of an antifungal cream such as efinaconazole (Jublia) and tavaborole (Kerydin) also works as effective treatments for this nail condition.
Onychomycosis Market Analysis
The increasing number of clinical developments to treat onychomycosis is a major trend influencing the market growth. Such developments by key players are boosting the demand for treatment for onychomycosis, further boosting the onychomycosis market growth. The increasing approvals of drugs by regulatory bodies for the treatment of onychomycosis are influencing the market growth as well. The increasing investments by pharmaceutical companies in research and development activities to develop novel therapies are majorly expected to drive market growth as well.
The increasing research and development activities to find new treatments or study existing treatments to find their efficacy while looking for scope for improvement are also responsible for the market growth. For example, a meta-analysis study exhibited the efficacy of terbinafine, posted on Oxford Academic. The study mentioned how the efficacy of treatment with terbinafine increased with the increase in treatment duration which was 12 weeks expanded to 24 weeks.
Onychomycosis Market Segmentations
Market Breakup by Treatment Type
- Drugs
- Laser Therapy
- Photodynamic Therapy
- Others
Market Breakup by Type
- Distal Subungual Onychomycosis
- White Superficial Onychomycosis
- Proximal Subungual Onychomycosis
- Other Types
Market Breakup by Route of Administration
- Oral
- Topical
Market Breakup by End User
- Hospitals
- Dermatology and Podiatry Clinics
- Offline Pharmacies
- Online Stores
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Onychomycosis Market Overview
The increasing prevalence of onychomycosis is a major factor driving the market growth. The prevalence of onychomycosis is great among older people with certain risk factors such as diabetes and weakened immune systems. The market is also driven by the continuous research and developments by key players in the market to develop effective and innovative treatments coupled with increased investments. The increased number of clinical trials to find the efficacy of antifungal drugs for the treatment of onychomycosis such as terbinafine, itraconazole, and fluconazole is also responsible for the onychomycosis market growth.
The increasing awareness about onychomycosis and its treatment options among patients and healthcare providers which helped the patients to get the condition diagnosed on an early basis and get treated, further increasing the demand for medications in the market. This awareness is greatly expected to further influence the market growth. The widespread availability of improved healthcare infrastructure has also played a vital role in the market growth as people are able to access the healthcare facility nearest to them and get better treatment options.
Onychomycosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Bayer AG
- Pfizer Inc.
- Abbott
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- GSK Plc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Onychomycosis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Onychomycosis Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.2 France Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.4 Japan Onychomycosis Disease Epidemiology Forecast (2017-2032)
6 Onychomycosis Market Overview – 7MM
6.1 Onychomycosis Market Historical Value (2017-2023)
6.2 Onychomycosis Market Forecast Value ( 2024-2032)
7 Onychomycosis Market Landscape – 7MM
7.1 Onychomycosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Onychomycosis: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Diagnosis Method
8 Onychomycosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Onychomycosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Onychomycosis Market Segmentation – 7MM
11.1 Onychomycosis Market by Treatment Type
11.1.1 Market Overview
11.1.2 Drugs
11.1.3 Laser Therapy
11.1.4 Photodynamic Therapy
11.1.5 Others
11.2 Onychomycosis Market by Type
11.2.1 Market Overview
11.2.2 Distal Subungual Onychomycosis
11.2.3 White Superficial Onychomycosis
11.2.4 Proximal Subungual Onychomycosis
11.2.5 Other Types
11.3 Onychomycosis Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Topical
11.4 Onychomycosis Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Dermatology and Podiatry Clinics
11.4.4 Offline Pharmacies
11.4.5 Online Stores
11.5 Onychomycosis Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Onychomycosis Market
12.1 Onychomycosis Market Historical Value (2017-2023)
12.2 Onychomycosis Market Forecast Value (2024-2032)
12.3 Onychomycosis Market by Type
12.4 Onychomycosis Market by Treatment Type
13 EU-4 and United Kingdom Onychomycosis Market
13.1 Onychomycosis Market Historical Value (2017-2023)
13.2 Onychomycosis Market Forecast Value (2024-2032)
13.3 Germany Onychomycosis Market Overview
13.3.1 Onychomycosis Market by Type
13.3.2 Onychomycosis Market by Treatment Type
13.4 France Onychomycosis Market Overview
13.4.1 Onychomycosis Market by Type
13.4.2 Onychomycosis Market by Treatment Type
13.5 Italy Onychomycosis Market Overview
13.5.1 Onychomycosis Market by Type
13.5.2 Onychomycosis Market by Treatment Type
13.6 Spain Onychomycosis Market Overview
13.6.1 Onychomycosis Market by Type
13.6.2 Onychomycosis Market by Treatment Type
13.7 United Kingdom Onychomycosis Market Overview
13.7.1 Onychomycosis Market by Type
13.7.2 Onychomycosis Market by Treatment Type
14 Japan Onychomycosis Market
14.1 Onychomycosis Market Historical Value (2017-2023)
14.2 Onychomycosis Market Forecast Value (2024-2032)
14.3 Onychomycosis Market by Type
14.4 Onychomycosis Market by Treatment Type
14.5 Onychomycosis Market by Region
14.5.1 Market Overview
14.5.2 United States
14.5.3 EU-4 and the United Kingdom
14.5.3.1 Germany
14.5.3.2 France
14.5.3.3 Italy
14.5.3.4 Spain
14.5.3.5 United Kingdom
14.5.4 Japan
15 United States Onychomycosis Market
15.1 Onychomycosis Market Historical Value (2017-2023)
15.2 Onychomycosis Market Forecast Value (2024-2032)
15.3 Onychomycosis Market by Type
15.4 Onychomycosis Market by Treatment Type
16 EU-4 and United Kingdom Onychomycosis Market
16.1 Onychomycosis Market Historical Value (2017-2023)
16.2 Onychomycosis Market Forecast Value (2024-2032)
16.3 Germany Onychomycosis Market Overview
16.3.1 Onychomycosis Market by Type
16.3.2 Onychomycosis Market by Treatment Type
16.4 France Onychomycosis Market Overview
16.4.1 Onychomycosis Market by Type
16.4.2 Onychomycosis Market by Treatment Type
16.5 Italy Onychomycosis Market Overview
16.5.1 Onychomycosis Market by Type
16.5.2 Onychomycosis Market by Treatment Type
16.6 Spain Onychomycosis Market Overview
16.6.1 Onychomycosis Market by Type
16.6.2 Onychomycosis Market by Treatment Type
16.7 United Kingdom Onychomycosis Market Overview
16.7.1 Onychomycosis Market by Type
16.7.2 Onychomycosis Market by Treatment Type
17 Japan Onychomycosis Market
17.1 Onychomycosis Market Historical Value (2017-2023)
17.2 Onychomycosis Market Forecast Value (2024-2032)
17.3 Onychomycosis Market by Type
17.4 Onychomycosis Market by Treatment Type
18 Regulatory Framework
18.1 Regulatory Overview
18.1.1 US FDA
18.1.2 EU EMA
18.1.3 INDIA CDSCO
18.1.4 JAPAN PMDA
18.1.5 Others
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Merck & Co., Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Teva Pharmaceutical Industries Ltd.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Cipla Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bayer AG
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Pfizer Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Abbott
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Novartis AG
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Sun Pharmaceutical Industries Ltd.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Bausch Health Companies Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 GSK Plc.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
23 Onychomycosis - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 4 billion in 2023, driven by the increasing research and development.
The market is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 and is likely to reach a market value of USD 6.3 billion by 2032.
The increasing incidence of chronic diseases such as diabetes, onychomycosis, and increasing geriatric population are among major factors driving market growth.
The increasing investments by pharmaceutical companies in research and development activities for the development of new therapies are among the major trends influencing market growth.
The major regions of the market include United States, Japan, EU-4 and the United Kingdom. EU-4 includes Germany, France, Italy, and Spain.
Different types of treatments include drugs, laser therapy, and photodynamic therapy, among others.
There are various kinds of onychomycosis, distal subungual onychomycosis, white superficial onychomycosis, and proximal subungual onychomycosis, among other types.
The different routes of administration are oral and topical.
End users in the market are hospitals, dermatology and podiatry clinics, offline pharmacies, and online stores, among others.
Key players involved in the market are Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Bayer AG, Pfizer Inc., Abbott, GSK Plc., Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., and Novartis AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER